This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
by Zacks Equity Research
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
ABBVPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
by Kinjel Shah
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
BIIBPositive Net Change LLYPositive Net Change
biotechs
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
by Zacks Equity Research
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
NVSPositive Net Change PFEPositive Net Change PTCTPositive Net Change OLMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
by Zacks Equity Research
INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.
GSKPositive Net Change INCYPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechnology biotechs pharmaceuticals
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
GSKPositive Net Change ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
by Zacks Equity Research
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. Shares rise on this leadership transition.
BEAMPositive Net Change SPRONegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
by Zacks Equity Research
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
MRKPositive Net Change SMMTPositive Net Change TILNegative Net Change BNTXPositive Net Change
biotechs medical pharmaceuticals
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Affimed's acimtamig in combination with AlloNK for treating Hodgkin lymphoma. Shares fall.
SPRONegative Net Change CSTLPositive Net Change ARTVPositive Net Change
biotechs
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
by Zacks Equity Research
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Denali Starts Dosing in Phase II Parkinson's Disease Study
by Zacks Equity Research
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
SNYPositive Net Change BIIBPositive Net Change SPRONegative Net Change DNLIPositive Net Change
biotechnology biotechs medical pharmaceuticals
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
by Zacks Equity Research
Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change TARANegative Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
by Zacks Equity Research
NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.
SNYPositive Net Change NVOPositive Net Change NVAXPositive Net Change
biotechs medical pharmaceuticals vaccines
GSK Expands Vaccine Collaboration With Zhifei in China
by Zacks Equity Research
GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.
GSKPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals vaccines
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises.
SPRONegative Net Change STOKPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
RHHBYPositive Net Change PFEPositive Net Change GILDNegative Net Change HALOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLC
by Zacks Equity Research
This is the first breakthrough therapy designation granted to MRK's sacituzumab tirumotecan in the United States.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
by Zacks Equity Research
CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.
BAYRYPositive Net Change CYTKNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
by Zacks Equity Research
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
PFEPositive Net Change GILDNegative Net Change PCRXNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
by Zacks Equity Research
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
PFEPositive Net Change GILDNegative Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
by Zacks Equity Research
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change MRUSPositive Net Change
biotechnology biotechs medical pharmaceuticals
JANX Stock Hits Record High on Prostate Cancer Study Data
by Zacks Equity Research
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.
SPRONegative Net Change CSTLPositive Net Change JANXPositive Net Change
biotechs medical
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise.
SPRONegative Net Change RZLTPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested in the stock for now.
JNJPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
by Zacks Equity Research
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
NVSPositive Net Change PFEPositive Net Change PTCTPositive Net Change OLMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
by Zacks Equity Research
CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.
BAYRYPositive Net Change CYTKNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals